Pfizer, Inc. v. Lee’s Empirical Analysis
2014
Citation profile
1 federal appellate ·
Relationships
Applies 35 U.S.C. § 111 · 35 U.S.C. § 132 · 35 U.S.C. § 154 · 5 U.S.C. § 702 · 5 U.S.C. § 706
Relies on Celotex Corporation v. Catrett H · Chevron U. S. A. Inc. v. Natural Resources Defense Council, Inc. · Skidmore v. Swift & Co. · Friends of the Earth Incorporateds v. Laidlaw Environmental Services Inc · Steffel v. Thompson
Most-quoted passages
The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 1 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.
“(i) an “A-Delay,” which awards PTA for delays arising from the USPTO’s failure to act by certain examination deadlines; (ii) a “B-Delay,” which awards PTA for an application pendency exceeding three years; and (iii) a “C-Delay,” which awards PTA.for delays due to interferences, secrecy orders, and appeals. The USPTO calculates PTA by adding the A-, B-, and C-Delays, subtracting any overlapping days, and then- subtracting any days attributable to applicant delay.”
1 later decision quote this exact passage · from the majoritye.g. Pfizer, Inc. v. Lee
How this case has been treated — in progress
Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.